Drug intelligence / Profile preview

LC-Z300-01

Development stage: Phase 3
Lead developer: Shanghai ChangZheng Hospital
Modality: Small Molecules
Administration: Oral

Overview

LC-Z300-01 is an orally administered polysaccharide derived from sugar cane or bamboo cane, under development as a therapeutic agent for type 2 diabetes and diabetic nephropathy. It is described in clinical trials as a dietary supplement or herbal medicine, with its primary mechanism of action not yet fully elucidated. The drug is being evaluated for its efficacy in lowering blood glucose and reducing proteinuria in patients with diabetic nephropathy, potentially slowing the progression of kidney disease. Clinical studies are ongoing to assess its safety and effectiveness[1][5][8].

Other names: Bamboo cane polysaccharide

Beyond the preview

Go deeper on LC-Z300-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LC-Z300-01.

Explore the full profile